Fusen Pharmaceutical Company Limited
福森藥業有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1652)

VOLUNTARY ANNOUNCEMENT
APPLICATION FOR LAUNCHING
"METFORMIN EMPAGLIFLOZIN TABLETS (I)" ACCEPTED

The board of directors (the "**Board**") of Fusen Pharmaceutical Company Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that the application for launching "Metformin Empagliflozin Tablets (I)", developed by Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Company Limited* (嘉亨(珠海橫琴)醫藥科技有限公司), a wholly-owned subsidiary of the Group, has been submitted to and accepted by the National Medical Products Administration of the People's Republic of China. The product is used for the treatment of the following diseases: in conjunction with diet control and exercise, it is suitable for adult patients with type 2 diabetes who are receiving treatment with Empagliflozin and Metformin Hydrochloride to improve the blood glucose control of such patients.

"Metformin Empagliflozin Tablets (I)" is a compound preparation consisting of Metformin Hydrochloride and Empagliflozin. Its pharmacological effects are as follows: Metformin reduces hepatic glucose production, inhibits intestinal absorption of glucose, and increases the uptake and utilization of glucose in peripheral tissues. It improves insulin sensitivity by increasing peripheral glucose uptake and utilization. Empagliflozin is an SGLT2 inhibitor that reduces renal glucose reabsorption, lowers the renal glucose threshold, and promotes the excretion of glucose in the urine. Both components have a synergistic effect in terms of mechanism and offer better hypoglycemic effect compared to ordinary single preparation.

The National Health Commission of the People's Republic of China has released the latest "Medium and Long-term Plan for the Prevention and Control of Chronic Diseases in China (2017–2025)", which sets the ultimate goals for 2025. Pursuant to which, the standardized management rate and core knowledge awareness rate of diabetes patients shall reach 70%, leading to an increased demand for diabetes medications. Metformin Empagliflozin Tablets (I) is classified as a Category B medical insurance product and offers advantages such as good hypoglycemic effect, no severe adverse reactions and good patient tolerance. Bioequivalence tests conducted on fasting and postprandial basis have demonstrated that the

bioequivalence between this product and the reference product is consistent. Metformin Empagliflozin Tablets (I) provides a very favorable risk-to-benefit ratio for improving blood glucose control of adult patients with type 2 diabetes.

The directors believe that Metformin Empagliflozin Tablets (I) is another important product for the Group, which further enriches the Group's product pipeline in the field of diabetes treatment. After the launch of this product, it will provide a wider range of treatment options for the majority of diabetic patients.

By order of the Board
Fusen Pharmaceutical Company Limited
Cao Changcheng
Chairman and Executive Director

Hong Kong, 3 April 2024

As at the date of this announcement, the Board of the Company comprises Mr. Cao Changcheng (Chairman), Mr. Hou Taisheng, Mr. Chi Yongsheng, Ms. Meng Qingfeng and Mr. Cao Zhiming as executive Directors, and Mr. Sze Wing Chun, Mr. Lee Kwok Tung Louis and Dr. To Kit Wa as independent non-executive Directors.